TY - JOUR
T1 - MiNDAUS partnership
T2 - a roadmap for the cure and management of motor Neurone disease
AU - Vucic, Steve
AU - Wray, Naomi
AU - Henders, Anjali
AU - Henderson, Robert D.
AU - Talman, Paul
AU - Mathers, Susan
AU - Bellgard, Matthew
AU - Aoun, Samar
AU - Birks, Carol
AU - Thomas, Gethin
AU - Hansen, Catherine
AU - Thomas, Geoff
AU - Hogden, Anne
AU - Needham, Merrilee
AU - Schultz, David
AU - Soulis, Tina
AU - Sheean, Bec
AU - Milne, Jane
AU - Rowe, Dominic
AU - Zoing, Margie
AU - Kiernan, Matthew C.
PY - 2022
Y1 - 2022
N2 - An innovative approach to patient management, evidence-based policy development, and clinical drug trials is required to provide personalized care and to improve the likelihood of finding an effective treatment for Motor Neurone Disease (MND). The MiNDAus Partnership builds on and extends existing national collaborations in a targeted approach to improve the standard and coordination of care for people living with MND in Australia, and to enhance the prospects of discovering a cure or treatment. Relationships have been developed between leading clinical and research groups as well as patient-centered organizations, care providers, and philanthropy with a shared vision. MiNDAus has established a corporate structure and meets at least biannually to decide on how best to progress research, drug development, and patient management. The key themes are; (i) empowering patients and their family carers to engage in self-management and ensure personalized service provision, treatment, and policy development, (ii) integration of data collection so as to better inform policy development, (iii) unifying patients and carers with advocacy groups, funding bodies, clinicians and academic institutions so as to inform policy development and research, (iv) coordination of research efforts and development of standardized national infrastructure for conducting innovative clinical MND trials that can be harmonized within Australia and with international trials consortia. Such a collaborative approach is required across stakeholders in order to develop innovative management guidelines, underpinned by necessary and evidence-based policy change recommendations, which, will ensure the best patient care until a cure is discovered.
AB - An innovative approach to patient management, evidence-based policy development, and clinical drug trials is required to provide personalized care and to improve the likelihood of finding an effective treatment for Motor Neurone Disease (MND). The MiNDAus Partnership builds on and extends existing national collaborations in a targeted approach to improve the standard and coordination of care for people living with MND in Australia, and to enhance the prospects of discovering a cure or treatment. Relationships have been developed between leading clinical and research groups as well as patient-centered organizations, care providers, and philanthropy with a shared vision. MiNDAus has established a corporate structure and meets at least biannually to decide on how best to progress research, drug development, and patient management. The key themes are; (i) empowering patients and their family carers to engage in self-management and ensure personalized service provision, treatment, and policy development, (ii) integration of data collection so as to better inform policy development, (iii) unifying patients and carers with advocacy groups, funding bodies, clinicians and academic institutions so as to inform policy development and research, (iv) coordination of research efforts and development of standardized national infrastructure for conducting innovative clinical MND trials that can be harmonized within Australia and with international trials consortia. Such a collaborative approach is required across stakeholders in order to develop innovative management guidelines, underpinned by necessary and evidence-based policy change recommendations, which, will ensure the best patient care until a cure is discovered.
KW - biomarker
KW - clinical trials
KW - MiNDAus
KW - MND
KW - models
UR - http://www.scopus.com/inward/record.url?scp=85116352484&partnerID=8YFLogxK
UR - http://purl.org/au-research/grants/NHMRC/1132524
UR - http://purl.org/au-research/grants/NHMRC/1153439
UR - http://purl.org/au-research/grants/NHMRC/1156093
U2 - 10.1080/21678421.2021.1980889
DO - 10.1080/21678421.2021.1980889
M3 - Review article
AN - SCOPUS:85116352484
SN - 2167-8421
VL - 23
SP - 321
EP - 328
JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
IS - 5-6
ER -